Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 223.4 SEK -2.27% Market Closed
Market Cap: 30.2B SEK
Have any thoughts about
Vitrolife AB?
Write Note

Vitrolife AB
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vitrolife AB
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Vitrolife AB
STO:VITR
Cash Equivalents
kr925m
CAGR 3-Years
-42%
CAGR 5-Years
9%
CAGR 10-Years
23%
Biogaia AB
STO:BIOG B
Cash Equivalents
kr1.5B
CAGR 3-Years
2%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash Equivalents
kr153.2m
CAGR 3-Years
-12%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Probi AB
STO:PROB
Cash Equivalents
kr305.4m
CAGR 3-Years
5%
CAGR 5-Years
16%
CAGR 10-Years
12%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash Equivalents
kr594m
CAGR 3-Years
41%
CAGR 5-Years
-11%
CAGR 10-Years
0%
BioArctic AB
STO:BIOA B
Cash Equivalents
kr611.6m
CAGR 3-Years
-15%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

Vitrolife AB
Glance View

Market Cap
30.2B SEK
Industry
Biotechnology

Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 427 full-time employees. The company went IPO on 2001-06-26. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. The company also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The firm is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.

VITR Intrinsic Value
140.46 SEK
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Vitrolife AB's Cash Equivalents?
Cash Equivalents
925m SEK

Based on the financial report for Sep 30, 2024, Vitrolife AB's Cash Equivalents amounts to 925m SEK.

What is Vitrolife AB's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
23%

Over the last year, the Cash Equivalents growth was 19%. The average annual Cash Equivalents growth rates for Vitrolife AB have been -42% over the past three years , 9% over the past five years , and 23% over the past ten years .

Back to Top